Fouo Pharmaceutical Technology

Fouo Pharma is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the discovery and development of next-generation precision oncology therapies. The company utilizes a proprietary structure-based drug design platform to create highly selective small molecule inhibitors that target specific genetic drivers of cancer. Its lead candidate, FWD1509, is a potent, irreversible inhibitor of EGFR and HER2 exon 20 insertion mutations, currently undergoing clinical evaluation for non-small cell lung cancer. Fouo Pharma's pipeline also includes targeted therapies for RET-driven cancers and other resistant mutations, aiming to provide effective treatments for patients with limited options. The company is backed by prominent venture capital firms and focuses on addressing significant unmet medical needs in the global oncology market.